News

HT-1 is a rare genetic disease in infants and children. It could lead to liver and kidney complications and become fatal if not treated. Orfadin is indicated as

The lead investigator of the double-blind placebo-controlled Phase II study is Dr. Tim Wigal. Dr. Wigal has been author or co-author of over 125 peer-reviewed articles about ADHD

The application was filed after the completion of the pre-clinical phase and proof-of-concept of the entourage technology and further to the Company’s preparations towards the development of a

This trial will study the use of CX-5461, a small molecule G-quadruplex stabilizer, to selectively kill tumors defective in the BRCA1/2 or HR related genes through the concept

The objective of these studies was to establish preliminary efficacy data in vivo for 10 separate repurposing candidates. Each of the candidates were identified using twoXAR’s computational drug

Gonitro is available in single-dose packets of a short-acting nitrate in a stabilized crystal granule form. Each Gonitro packet contains 400 mcg of nitroglycerin. The clinical data suggests

Deflazacort is a glucocorticoid with anti-inflammatory and immunosuppressant properties. It has fast track status, orphan drug designation and rare pediatric disease designation for DMD. One of the pivotal

Three-month follow-up data is anticipated to be available in the fourth quarter of this year. The company started the regulatory process for a phase II/III clinical trial for

"With our heritage in both rheumatology and dermatology, we are committed to providing physicians and patients a variety of biologic options, which are critical for the long-term management